Site Search

1. 21.
   AMP/assets/File/position-statements/2016/AMP-CAP-Comments-DL35000-NGS-MolecularPat...

   Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas are cystic lesions".. with the risk malignancy at around 62%" (NCCN Guidelines: Pancreatic Adenocarcinoma, ... In this study, 91% of patients with methylated ... pseudo-progression (versus 41% of patients without methylated ... ASXL1 in >80% of cases and SETBP1 ... ASXL1 in >80% of cases and SETBP1

   https://www.amp.org/AMP/assets/File/position-statements/2016/AMP-CAP-Comments-DL...
2. 22.
   AMP/assets/File/advocacy/AMP Response-HHS RFI on surge capactiy response-9-21-20...

   Respondents were laboratory professionals from various laboratory settings: 42% of respondents were from ... by using additional platforms (64% of respondents). The second most ... to other methods available (66% of respondents); Availability of testing reagents and supplies (58%); It would allow them to ... semi-automated method (50%); The platform was already

   https://www.amp.org/AMP/assets/File/advocacy/AMP Response-HHS RFI on surge capac...
3. 23.
   AMP/assets/File/awards/young_investigator/YIA18_WinningAbstracts2018.pdf?pass=8

   The first was biallelic loss at 8p11.22 (9/28, 32%), a region encoding ADAM metalloproteinase domains 3A, 5, and 18. The second was ... gain at 1p13.3 (6/28, 21%), corresponding to genes for glutathione-S ... transferase theta at 22q11.23 (8/28, 29%). Conclusions: Our results support the concept that ... were queried against gnomAD, only 30% of all germline variants in our

   https://www.amp.org/AMP/assets/File/awards/young_investigator/YIA18_WinningAbstr...
4. 24.
   AMP/assets/File/advocacy/AMP_USPTO_Comments_MPEP_Guidance_9_12_22.pdf?pass=7

   Moreover, fifty-three percent (53%) of respondents decided not to ... on patient access to genetic tests. https://osp.od.nih.gov/wp-content ... diagnostic tests. Furthermore, as the 4 https://www.nytimes.com/2013/06/14 ... 2021. 26 As one example, see https://www.wired.com/story/one-scientists ... COVID-19.” October 30, 2020. https://www.aclu.org/news/privacy-

   https://www.amp.org/AMP/assets/File/advocacy/AMP_USPTO_Comments_MPEP_Guidance_9_...
5. 25.
   AMP/assets/File/advocacy/AMP_USPTO_Comments_MPEP_Guidance_9_12_22.pdf?pass=99

   Moreover, fifty-three percent (53%) of respondents decided not to ... on patient access to genetic tests. https://osp.od.nih.gov/wp-content ... diagnostic tests. Furthermore, as the 4 https://www.nytimes.com/2013/06/14 ... 2021. 26 As one example, see https://www.wired.com/story/one-scientists ... COVID-19.” October 30, 2020. https://www.aclu.org/news/privacy-

   https://www.amp.org/AMP/assets/File/advocacy/AMP_USPTO_Comments_MPEP_Guidance_9_...
6. 26.
   AMP/assets/File/advocacy/FINAL_AMP_Position_Statement--Prior_Authorization_8_18_25...

   Indeed, another OIG report from 2022 confirmed that 13 1 https://www.kff.org/ ... in-2023/#:~:text=The%20vast%20majority%20of%20denied,of%20the%20prior%20authorization%20process. 2 https://oig.hhs.gov/oei/ ... 19-00350.asp 3 https://oig.hhs.gov/reports ... found that 29 4 https://oig.hhs.gov/reports ... authorization requests conflicts 10 https://www.ama-assn.org

   https://www.amp.org/AMP/assets/File/advocacy/FINAL_AMP_Position_Statement--Prior...
7. 27.
   AMP/assets/TechPosterAwardWinnerAbstracts.pdf?pass=97

   Of these samples, 62% were ordered for singleton/duo/trio exomes, and 38% for panels (NDD or CTD) and familial ... QC for NGS libraries show >90% of fragments consistently between 200bp and 700bp ... sample averaged >100x with 95% to 99% of analyzable target bases with at ... reads. Diagnostic yield was approximately 33%, dependent on test type. Sample extraction

   https://www.amp.org/AMP/assets/TechPosterAwardWinnerAbstracts.pdf?pass=97
8. 28.
   AMP/assets/AMPComments-VALIDAct-2-13-2019-FINAL.pdf?pass=56

   utm_campaign=Digital%20Health%20Update%3A%20New%20FDA%20Pre-Cert%20Working%20Model%20Now%20Available&utm_medium=email&utm_source=Eloqua 7 o (b)(2)(A)(iii) – Should the text ... the deficiency poses an immediate jeopardy to the patient or hazard to the general public. 4 https://jmd.amjpathol.org/article/S1525-1578(10)60253-X/pdf 10 o AMP’s CLIA modernization

   https://www.amp.org/AMP/assets/AMPComments-VALIDAct-2-13-2019-FINAL.pdf?pass=56
9. 29.
   AMP/assets/AMPComments-VALIDAct-2-13-2019-FINAL.pdf?pass=63

   utm_campaign=Digital%20Health%20Update%3A%20New%20FDA%20Pre-Cert%20Working%20Model%20Now%20Available&utm_medium=email&utm_source=Eloqua 7 o (b)(2)(A)(iii) – Should the text ... the deficiency poses an immediate jeopardy to the patient or hazard to the general public. 4 https://jmd.amjpathol.org/article/S1525-1578(10)60253-X/pdf 10 o AMP’s CLIA modernization

   https://www.amp.org/AMP/assets/AMPComments-VALIDAct-2-13-2019-FINAL.pdf?pass=63
10. 30.
    AMP/assets/File/advocacy/Coalition Letter to Biden Administration on Patent...

    L LIBRARY OF MED., https://www.ncbi.nlm.nih.gov/sars- ... U.S. FOOD AND DRUG ADMIN., https://www.fda.gov/consumers/consumer-updates ... CTRS. FOR DISEASE CONTROL AND PREVENTION, https://www.cdc.gov/coronavirus/2019-ncov ... 2.5 million new patents (over 20% U.S. patents ever issued). 16 ... Venture Monitor, 4Q 2018 at 19, https://files.pitchbook.com/website/files/pdf

    https://www.amp.org/AMP/assets/File/advocacy/Coalition Letter to Biden Administr...